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1. Introduction 
Glutamine phosphoribosylpyrophosphate (PRPP) 
amidotransferase (amidophosphoribosyltransferase, 
EC 2.4.2.14) was markedly increased in all hepatomas 
examined and the sensitivity of-the hepatoma enzyme 
to feedback inhibition by AMP was an order of mag- 
nitude less than that of the liver enzyme. These ob- 
servations are of special relevance in the elucidation 
of the reprogramming of gene expression in cancer 
because amidotransferase is the first enzyme commit- 
ted to channeling PRPP into de novo purine biosynthe- 
sis and it is subject to stringent feedback regulation [ 1 ] 
2. Materials and methods 
2.1. Animals and tissues 
Inbred strain male Buffalo and ACI/N rats carry- 
ing bilateral subcutaneous transplants of hepatoma 
lines of different growth rates were maintained in 
separate cages with water and Purina Chow avail- 
able ad libitum. Control normal rats of the same 
strains were sacrificed along with tumor-bearing rats. 
The handling of the tumor-bearing animals, the pre- 
paration of the regenerating liver, the investigation 
in developing rats, the killing of animals and excision 
of livers and tumors were conducted as outlined 
previously [2]. The relevant biological aspects [3] 
and biochemical properties [2] of the different 
transplantable tumor lines in the spectrum of hepato- 
mas of different growth rates were reported elsewhere. 
* To whom correspondence should be sent. 
North-Holland Publishing Company - Amsterdam 
2.2. Preparation of extracts for enzyme assay 
20% Homogenates (w/v) were prepared from nor- 
mal liver and tumor tissues in 0.25 M sucrose contain- 
ing 1 mM MgClz [4]. The homogenate was centri- 
fuged at 100 000 g for 30 min at 0°C in Spinco ultra- 
centrifuge and the clear supernate was used for assays. 
Careful kinetic studies were carried out to insure 
proportionality with elapsed time and amount of 
enzyme added. 
2.3. i%e glutamine PRPP amidotransferase assay 
sys tern 
As a result of such investigations a standard as- 
say system was worked out which was an adaptation 
of that of Katunuma et al. [4] to the kinetic condi- 
tions of the rat liver and hepatoma systems. The 
reaction mixture contained in final concentrations: 
PRPP 10 mM, glutamine 20 mM, MgClz 15 mM, 
Tris-HCl buffer (50 mM), pH 7.2, and KF 1 .O mM. 
The reactions were carried out at 37°C and they were 
stopped at 0, 30, and 45 min of incubation by boiling 
for exactly 5 min. The tubes were centrifuged and in 
the clear supernate the concentration of glutamic acid, 
that had formed in presence of PRPP, was determined. 
This was carried out by coupling to the reduction of 
NAD in presence of added excess glutamate dehydro- 
genase in a Gilford 2000 recording spectrophotometer. 
Under these experimental conditions no PRPP depen- 
dent ammonia was liberated from glutamine, indicating 
that glutaminase activity did not interfere with this 
assay. The results were calculated in pmoles/hr/g 
wet weight of tissue and were expressed as specific 
activities in pmoles of substrate metabolized per hr 
per mg protein. 
53 
Volume 49, number 1 FEBS LETTERS Decemtm 1974 
3. Results and discussion 
3.1. Comparison of glutamine PRPP amidotransferase 
activity in normal and regenerating rat liver and in 
hepatomas of different growth rates 
Table 1 indicates that in normal liver the amido- 
transferase specific activity varied from 4.4 to 8.2 
pmoles substrate metabolized per hr per mg protein 
X 10e2. Taking these values as lOO%, the activities in 
the slow growing hepatomas 66, 20, 8999,47C, and 
44 were 170, 209, 317, 251, and 259%, respectively, 
Table 1 
Increased glutamine PRPP amidotransferase 






tein X 1 O-* ) 
Normal liver (Buffalo) 
Control for 20 
Control for 66 
Control for 47C 
Control for 8999 
Control for 44 
Control for 1177 
Control for 96 18A2 
Normal liver (ACl/N) 
Control for 3924A 














11.5 9.3 + 0.6 (209)* 
10.2 11.5 + 0.6 (170)* 
1.0 17.1 ? 0.7 (251)* 
6.5 22.0 i 0.5 (317)* 
5.4 21.1 i 0.2 (259)* 
1.0 20.3 i 1.6 (303)* 
0.9 14.7 * 0.5 (195)* 
0.6 15.1 * 0.9 (278)* 
0.5 15.6 ?r 1.5 (309)* 
4.4 + 0.4 (100) 
6.8 * 0.4 (100) 
6.8 f; 0.5 (100) 
6.9 + 0.1 (100) 
8.2 r 1.1 (100) 
6.7 + 0.8 (100) 
5.1 + 0.4 (100) 
7.5 * 0.5 (100) 
5.4 t 0.4 (100) 
7.0 + 0.4 (100) 
7.9 i 0.6 (114) 
The data are given as means f S.E. of 3 to 10 rats in the vari- 
ous groups with percentages of corresponding control liver 
values in parentheses. The specific activities are to be multi- 
plied by the exponential given to arrive at the actual values. 
Growth rate is expressed as the mean transplantation time 
in months between inoculation and growth to 1.5 cm diameter. 
* Values statistically significantly different from the respec- 
tive controls (p < 0.05). 
of the activities of corresponding normal rat livers. 
In the rapidly growing hepatomas 7777, 3924A. 3683, 
and 9618A2 the specific activities were 303, 195, 278, 
and 309%, respectively, of the normal liver values. 
The amidotransferase activity in the 24-hr regener- 
ating liver was not different from that of the liver of 
sham-operated control rats. Investigation in rats at 6 
days and at 4 weeks of age showed that the amido- 
transferase activities were less than one-third of 
those in the adult rat liver. As the increased amido- 
transferase activity was present only in the liver tumors, 
and it did not occur in rapidly growing differentiating 
or regenerating liver, the increased activity of this key 
purine synthesizing enzyme appears to be specific to 
the neoplastic transformation. 
Since in the assays the enzyme activity was propor- 
tionate with the enzyme amount, it is assumed that the 
increased enzyme activity in the hepatomas represents 
increased enzyme concentration in the neoplasms. The 
rigorous verification of this assumption by a method 
independent from the assay of enzyme activity, such 
as by immunological technics, should be available, 
since the purification and immunotitration of liver 
and hepatoma enzymes are in progress in this labo- 
ratory. 
3.2. Alteration of feedback inhibition by AMP on 
glutamine PRPP amidotransferase in hepatoma 
3924A 
In examining the feedback inhibition exerted by 
AMP, it was observed during in vitro studies that the 
amidotransferase in rapidly growing hepatoma 3924A 
was more than 10 times less sensitive to the inhibitory 
action of AMP (Ki = 1.5 mM) than the enzyme from 
normal liver (Ki = 0.1 mM). The inhibition by AMP 
was relieved in both liver and hepatoma by high 
concentrations (10 mM) of PRPP. The kinetics of 
this inhibition is in agreement with reports on 
chicken and rat liver enzyme [4]. 
The observation that amidotransferase activity 
was increased 2- to 3-fold in all hepatomas, irrespec- 
tive of the degree of malignancy, differentiation, or 
growth rate, is important, since it suggests that the 
reprogramming of gene expression that occurs in 
malignant transformation is linked with an increase 
in the expression of this key purine-synthesizing en- 
zyme activity. In our laboratories to date we discov- 
ered 4 such malignant transformation-linked increases 
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in enzyme activities, and they all relate to an increased 
potential in the channeling of precursors to key bio- 
synthetic processes. Thus, the increase in the activi- 
ties of glucose 6-phosphate dehydrogenase and trans- 
aldolase provides an increased potential for routing 
glycolytic intermediates into pentose phosphate bio- 
synthesis [S 1. In turn, the presently reported increase 
in amidotransferase activity should provide an increased 
potential for purine biosynthesis. The fourth alteration 
observed in all hepatomas was an increase in UDP ki- 
nase activity (J. C. Williams, G. Weber, in preparation) 
which also provides an increased potential for nuclei 
acid biosynthesis. 
3.3. Glutamine PRPPamidotransferase activity in rat 
kidne_y tumors 
The increased amidotransferase activity is not re- 
stricted to liver tumors, since we also observed in two 
series of transplantable rat kidney tumors of different 
growth rates that this enzyme activity was elevated 2- 
to 3-fold over that of normal kidney. Increased amido- 
transferase activity was also reported in the spleen of 
Friend leukemia-bearing mice [6]. In addition to the 
presence of an increased enzyme concentration in the 
hepatomas, we provide evidence that the increased 
enzyme activities at PRPP concentrations that may 
approach the physiological levels are much less sen- 
sitive to normal feedback inhibition exerted by AMP. 
Since the level of AMP is in the range of 0.3 to 0.5 
mM in these hepatomas (7), it is likely that the hepa- 
toma enzyme under in vivo circumstances is deinhibit- 
ed from the influence of AMP. Work is in progress to 
elucidate whether the decreased sensitivity to feedback 
inhibition by AMP was due to an alteration in the 
hepatoma amidotransferase nzyme protein or the 
hepatoma enzyme is an isozyme different from that 
contained in normal liver. 
4. Conclusions 
Glutamine phosphoribosylpyrophosphate (PRPP) 
amidotransferase (EC 2.4.2.14) was increased 2- to 3- 
fold in all examined hepatomas irrespective to the 
tumor growth rate and the degrees of histological 
differentiation. Amidotransferase in rapidly growing 
hepatomas was much less sensitive to inhibitory action 
of AMP (Ki = 1.5 mM) than the enzyme from normal 
liver (Ki = 0.1 mM). Since reprogramming of gene 
expression, as manifested in the increased activity of 
this key purine-synthesizing enzyme, was present only 
in hepatomas and not in rapidly growing differentiating 
or regenerating liver, this increased enzyme activity 
appears to be specific to the neoplastic transformation. 
Much of the previous work in the hepatoma spec- 
trum emphasized the important alterations that are 
linked with the increase in tumor growth rate. These 
malignant progression-linked alterations in gene ex- 
pression include the increase in the activities of key 
glycolytic, pyrimidine and DNA synthesizing enzymes 
[8- 121. Concurrently, there was a progressive decrease 
in the activities of key enzymes of gluconeogenesis, 
pyrimidine catabolism and the urea cycle [ 13- 151. 
In addition to this progression-linked metabolic im- 
balance we now provide new observations indicating 
that the reprogramming of gene expression in the 
cancer cells entails transformation-linked alterations such 
as we report for the marked increase in activity of the 
key purine-synthesizing enzyme, glutamine PRPP 
amidotransferase. Since the tumors contain more 
amidotransferase activity and the enzyme is less sen- 
sitive to physiological regulation, this reprogramming 
of gene expression should confer a selective biological 
advantage to the cancer cells. 
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